Tirzepatide vs Semaglutide: Which GLP-1 Medication Is Better?
| Category | Tirzepatide | Semaglutide |
|---|---|---|
| Drug Class | Dual GLP-1/GIP receptor agonist | GLP-1 receptor agonist |
| Mechanism | Activates both GLP-1 and GIP receptors for dual incretin effect | Activates GLP-1 receptors only |
| Brand Names (Diabetes) | Mounjaro | Ozempic, Rybelsus |
| Brand Names (Weight Loss) | Zepbound | Wegovy |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Max Weight Loss (Trials) | 22.5% (SURMOUNT-1, 15 mg, 72 weeks) | 14.9% (STEP 1, 2.4 mg, 68 weeks) |
| Dosing Frequency | Once weekly (injection) | Once weekly (injection) or once daily (oral Rybelsus) |
| Dose Range | 2.5 mg to 15 mg weekly | 0.25 mg to 2.4 mg weekly (injectable) |
| FDA Approval (Diabetes) | May 2022 (Mounjaro) | December 2017 (Ozempic) |
| FDA Approval (Weight) | November 2023 (Zepbound) | June 2021 (Wegovy) |
| Common Side Effects | Nausea (24-33%), diarrhea (18-23%), vomiting (7-13%) | Nausea (20-44%), diarrhea (15-30%), vomiting (6-24%) |
| Cost (Without Insurance) | $1,000-$1,200/month | $900-$1,350/month |
| Cardiovascular Outcomes | CV outcomes trial (SURPASS-CVOT) ongoing | SELECT trial: 20% MACE reduction (Wegovy) |
| Oral Formulation | Not available | Yes (Rybelsus, for T2D only) |
How Do Tirzepatide and Semaglutide Compare?
Tirzepatide and semaglutide are both injectable incretin-based medications used for type 2 diabetes and weight management, but they work through different mechanisms. Semaglutide targets only the GLP-1 receptor, while tirzepatide is a dual agonist that activates both GLP-1 and GIP receptors. This dual mechanism is believed to produce the greater weight loss and glucose improvement seen with tirzepatide in clinical trials. The SURPASS-2 trial provided direct head-to-head data: tirzepatide at all three doses (5, 10, and 15 mg) outperformed semaglutide 1 mg for both HbA1c reduction and weight loss in patients with type 2 diabetes. However, this trial compared tirzepatide against Ozempic (max 1 mg at the time), not the higher weight-management dose of 2.4 mg (Wegovy).
Weight Loss: What the Data Shows
Comparing the largest weight-management trials, tirzepatide 15 mg produced 22.5% weight loss over 72 weeks (SURMOUNT-1) while semaglutide 2.4 mg produced 14.9% over 68 weeks (STEP 1). This approximately 50% greater weight loss with tirzepatide is clinically meaningful, but cross-trial comparisons should be interpreted cautiously since the study populations, protocols, and timeframes differed. At the individual level, response to these medications varies significantly. Some patients achieve excellent results with semaglutide and do not need to switch, while others who plateau on semaglutide may benefit from switching to tirzepatide. The proportion of patients achieving surgical-level weight loss (20% or more) was notably higher with tirzepatide: over one-third of the 15 mg group vs approximately one-third of the semaglutide 2.4 mg group.
Side Effects and Tolerability
Both medications share a similar gastrointestinal side effect profile, which is expected given that they both activate GLP-1 receptors. Nausea, diarrhea, vomiting, and constipation are the most common adverse events with both drugs. In SURMOUNT-1, nausea rates with tirzepatide ranged from 24-33% depending on dose, while in STEP 1, nausea with semaglutide 2.4 mg was reported in 44%. However, direct comparison of these rates is problematic due to differences in trial design and reporting. Discontinuation rates due to adverse events were broadly similar: approximately 4-7% for tirzepatide across doses and 7% for semaglutide 2.4 mg. Both medications carry boxed warnings about thyroid C-cell tumors and warnings about pancreatitis, gallbladder disease, and acute kidney injury.
Choosing Between Tirzepatide and Semaglutide
The choice between these medications depends on several factors beyond raw efficacy data. Insurance coverage is often the primary determinant: many plans cover one but not the other, or require trying one before the other (step therapy). Semaglutide has the advantage of longer real-world experience (approved in 2017 vs 2022) and cardiovascular outcomes data from the SELECT trial. It also offers an oral formulation (Rybelsus) for patients who prefer to avoid injections. Tirzepatide may be preferred for patients seeking maximum weight loss, those who have not achieved adequate results with semaglutide, or those who respond better to the dual-agonist mechanism. Both are once-weekly injections with similar administration and storage requirements. Patients should discuss their specific situation with their healthcare provider.
- Consider tirzepatide if maximizing weight loss is the primary goal
- Consider semaglutide if cardiovascular risk reduction is important (SELECT trial data)
- Check insurance coverage for both before deciding
- Semaglutide offers an oral option (Rybelsus) if injection avoidance is a priority
- Switching from one to the other is possible if the first does not work well
- Both require the same lifestyle modifications: diet, exercise, and adequate protein
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary.
Frequently Asked Questions
For average weight loss, clinical trial data favors tirzepatide (22.5% vs 14.9%). However, "better" depends on individual factors including response, side effects, cost, insurance coverage, and treatment goals. Some patients respond well to semaglutide and do not need to switch. Semaglutide has more long-term safety data and proven cardiovascular outcomes in non-diabetic patients (SELECT trial).
Yes. Many patients switch, often because they have plateaued on semaglutide or want greater weight loss. No washout period is required. Most prescribers start tirzepatide at the 2.5 mg initiation dose regardless of the previous semaglutide dose. Some GI side effects may recur during the transition.
Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide activates only GLP-1. GIP receptor agonism is believed to enhance fat oxidation, improve lipid metabolism, and provide additional appetite suppression through complementary pathways. This dual mechanism likely explains the greater weight loss, though the exact contribution of each receptor pathway is still being studied.
Yes, the side effect profiles are very similar. Both cause primarily gastrointestinal symptoms: nausea, diarrhea, vomiting, and constipation. Both carry the same boxed warning about thyroid C-cell tumors and similar warnings about pancreatitis, gallbladder disease, and kidney injury. The rates and severity of these effects appear broadly comparable based on available trial data.
List prices are similar: approximately $1,000-$1,200/month for tirzepatide and $900-$1,350/month for semaglutide (depending on brand). Actual out-of-pocket cost depends heavily on insurance coverage and manufacturer savings programs. Both Eli Lilly and Novo Nordisk offer copay assistance for commercially insured patients. Eli Lilly has also introduced lower-cost Zepbound vials for cash-pay patients.
No. The only head-to-head trial (SURPASS-2) compared tirzepatide doses against semaglutide 1 mg (Ozempic dose) in a diabetes population. A direct comparison of tirzepatide 15 mg vs semaglutide 2.4 mg in a weight-management population has not been conducted. Cross-trial comparisons (SURMOUNT-1 vs STEP 1) are the best available data but have inherent limitations.